Advertisement News Archives - Page 205 of 5205 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

January 28, 2026

FDA accepts Otsuka’s centanafadine application for ADHD treatment

The US Food and Drug Administration (FDA) has accepted for priority review Otsuka Pharmaceutical’s new drug application (NDA) submitted for centanafadine, an investigational, once-daily extended-release capsule for attention-deficit hyperactivity disorder (ADHD) treatment.

FDA accepts Otsuka’s centanafadine application for ADHD treatment